N-Propargylglycine

N-Propargylglycine 是一种可穿透血脑屏障且具有口服活性的 PRODH 抑制剂,可共价修饰酶结合型 FAD 及活性位点赖氨酸,导致酶结构变形、蛋白质降解,并不可逆地抑制脯氨酸和 4-羟基脯氨酸的分解代谢,同时可诱导 UPRmt,上调线粒体伴侣蛋白与 YME1L1,增强线粒体蛋白质稳态,阻断星形胶质细胞对 L-脯氨酸的消耗,并消除 L-脯氨酸维持 ATP 水平及保护细胞活力的作用,还可促进神经进程,升高脑中脯氨酸、羟基脯氨酸和肌氨酸的水平,使亨廷顿病全脑转录组部分恢复正常,并可减少高草酸尿症,预防草酸钙结石形成,减轻肾小管损伤,恢复 Grhpr 基因敲除小鼠的体重与存活率,因此可用于乳腺癌、神经退行性疾病、亨廷顿病及 2 型原发性高草酸尿症的相关研究。
产品编号: MS-J53457 纯度: 99.70% CAS No.: 58160-95-5 分子式: C5H7NO2 分子量: 113.11
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

N-Propargylglycine 是一种可穿透血脑屏障且具有口服活性的 PRODH 抑制剂,可共价修饰酶结合型 FAD 及活性位点赖氨酸,导致酶结构变形、蛋白质降解,并不可逆地抑制脯氨酸和 4-羟基脯氨酸的分解代谢,同时可诱导 UPRmt,上调线粒体伴侣蛋白与 YME1L1,增强线粒体蛋白质稳态,阻断星形胶质细胞对 L-脯氨酸的消耗,并消除 L-脯氨酸维持 ATP 水平及保护细胞活力的作用,还可促进神经进程,升高脑中脯氨酸、羟基脯氨酸和肌氨酸的水平,使亨廷顿病全脑转录组部分恢复正常,并可减少高草酸尿症,预防草酸钙结石形成,减轻肾小管损伤,恢复 Grhpr 基因敲除小鼠的体重与存活率,因此可用于乳腺癌、神经退行性疾病、亨廷顿病及 2 型原发性高草酸尿症的相关研究。

生物实验数据

生物活性 N-Propargylglycine is a blood-brain barrier-permeable and orally active PRODH inhibitor that covalently modifies enzyme-bound FAD and the active-site lysine, leading to enzyme structural deformation, protein degradation, and irreversible inhibition of proline and 4-hydroxyproline catabolism; it also induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes the ability of L-proline to maintain ATP levels and protect cell viability, while promoting neurite outgrowth, elevating brain levels of proline, hydroxyproline, and sarcosine, partially restoring the whole-brain transcriptome in Huntington's disease, reducing hyperoxaluria, preventing calcium oxalate stone formation, alleviating renal tubular injury, and restoring body weight and survival in Grhpr knockout mice, and can therefore be used in research related to breast cancer, neurodegenerative diseases, Huntington's disease, and primary hyperoxaluria type 2.
体外研究
(In Vitro)

N-Propargylglycine (5 mM; 6 min/48 h) 可不可逆地抑制 ZR-75-1 人乳腺癌细胞线粒体中脯氨酸的氧化与 NADH 的生成,作用浓度为 5 mM;且在对培养细胞进行预处理 48 h 后,仍可观察到持续性抑制作用。
N-Propargylglycine (5 mM; 24-48 h) 可在处理 24 h 和 48 h 后诱导人乳腺癌 ZR-75-1 细胞中线粒体 PRODH 蛋白快速降解,并上调线粒体伴侣蛋白 GRP-75、HSP-60 以及蛋白酶 YME1L1 的表达,这与线粒体未折叠蛋白反应的激活一致。
N-propargylglycine (0.01-5 mM; 8 h) 可强效抑制原代培养大鼠星形胶质细胞中 L-脯氨酸的消耗,孵育 8 h 后,其半最大抑制浓度为 0.2 mM,在 1 mM 浓度下抑制率可达 80%以上。
N-Propargylglycine (5 mM; 48 h) 可将线粒体 HYPDH/PRODH2 的表达水平降至对照组的约 40%,从而促进该酶的线粒体降解。

Immunofluorescence

Cell Line: ZR-75-1 human breast cancer cells
Concentration: 5 mM
Incubation Time: 24 h; 48 h
Result: Showed significant loss of mitochondrial PRODH protein, with concurrent upregulation of mitochondrial GRP-75 and no change in mitochondrial TOM20 levels.
Decreased PRODH levels to 0.6-fold of control, increased GRP-75 levels to 2.2-fold of control, and increased HSP-60 levels to 1.3-fold of control in mitochondrial fractions.
Decreased PRODH levels to 0.75-fold of control, increased 60 kDa YME1L1 levels to 1.34-fold of control, and increased 80 kDa YME1L1 levels to 1.38-fold of control in whole-cell lysates (24 h treatment).
Decreased PRODH levels to 0.58-fold of control, maintained 60 kDa YME1L1 levels at 1.35-fold of control, and returned 80 kDa YME1L1 levels to 1.08-fold of control in whole-cell lysates (48 h treatment).

Western Blot Analysis

Cell Line: Human hepatocarcinoma HepG2 cells
Concentration: 5 mM
Incubation Time: 48 h
Result: Reduced mitochondrial HYPDH/PRODH2 expression levels to ~40% of untreated control levels.
Left non-specific bands in the cytoplasmic fraction insensitive to treatment.
体内研究
(In Vivo)

N-Propargylglycine (N-PPG) (50-200 mg/kg;口服;每日一次;连续 9 天) 可穿透小家鼠 (Mus musculus) 的血脑屏障,诱导脑内 PRODH 蛋白表达呈剂量依赖性降低,上调线粒体未折叠蛋白反应的标志物,且可显著激活神经通路,无明显毒性产生。
N-Propargylglycine (N-PPG) (灌胃,每日给药,连续 9 天,剂量 50 mg/kg) 可在 WT 小鼠中诱导大脑线粒体兴奋效应,使 Prodh 蛋白水平降低约 30%,并改变大脑转录组和肾脏代谢组特征。
N-Propargylglycine (N-PPG) (50 mg/kg;灌胃;每日;连续 9 天) 可诱导 R6/2 亨廷顿病 (HD) 小鼠的脑线粒体兴奋效应,并可部分逆转其转录组谱的异常。
N-Propargylglycine (N-PPG) (50 mg/kg;灌胃;每日;14 天) 在 R6/2 亨廷顿舞蹈症 (HD) 小鼠中耐受性良好,可提高脯氨酸、羟脯氨酸和肌氨酸的组织水平,但不改变疾病进展或生存期。
N-Propargylglycine (200 mg/kg;口服;每日 1 次;连续 5 天) 可将小鼠肝脏 Hypdh/Prodh2 和 Prodh1 的蛋白水平分别降至对照组的 73%和 66%。
N-Propargylglycine (50 mg/kg;口服;每日一次;连续 9 天) 可显著升高野生型小鼠和亨廷顿病模型小鼠肾脏中的 4-羟脯氨酸和脯氨酸水平,与对照组相比,升高倍数为 1.42 至 4.57。
N-Propargylglycine (50 mg/kg;口服;每日;连续 14 天) 可显著升高亨廷顿舞蹈病模型小鼠的血液 4-羟基脯氨酸水平至 3.59 倍,同时可分别将其脑内 4-羟基脯氨酸和脯氨酸水平升高至 2.72 倍和 2.57 倍。
N-Propargylglycine (200 mg/kg;口服;每日;连续 21 天) 可在 3 周后使 2 型原发性高草酸尿症 Grhpr 基因敲除小鼠的尿草酸排泄量降低约 32%,抑制 Ca2+Ox 晶体形成,恢复体重增长并维持肾功能。
N-Propargylglycine (200 mg/kg;口服;每日;持续至 24 周) 可在 24 周内将 2 型原发性高草酸尿症 Grhpr 基因敲除小鼠的存活率完全恢复至野生型水平,长期抑制高草酸尿症,阻止 Ca2+Ox 结石形成,并维持其肾功能与体重。

Animal Model: Mixed B6/CBA background (5-week-old; male and female)
Dosage: 50-200 mg/kg
Administration: p.o.; daily; 9 days
Result: Reduced mean brain PRODH protein expression.
Upregulated HSP-60 transcripts 1.68-fold and YME1L1 transcripts 1.35-fold relative to housekeeping genes (single 200 mg/kg treated mouse).
Increased median YME1L1 transcript levels by 18.5% (50 mg/kg, not statistically significant) and mean brain YME1L1 protein expression by 30-40%.
Identified 1324 differentially expressed genes, with 841 genes upregulated via RNAseq analysis.
Confirmed significant enrichment (FDR) of 77 Gene Ontology pathways and 7 Reactome neural pathways, including glutaminergic and GABAergic synapses, nervous system development, and voltage-gated ion channel pathways.
Upregulated neural genes 1.64-fold (Htr3a), 1.72-fold (Itpr1), 1.48-fold (Syt6), and 2.00-fold (Pcsk2) relative to GAPDH via RTqPCR validation.
Animal Model: R6/2 (male, ~4 weeks at receipt, Huntington's disease transgenic model expressing N-terminal human mutant HTT with ~150 CAG repeats)
Dosage: 50 mg/kg
Administration: oral gavage; daily; 9 days
Result: Induced brain mitohormesis with nominal (insignificant) declines in Prodh protein levels and increased expression of Yme1l1 protease and chaperone Grp78.
Partially normalized HD whole brain transcriptomes toward WT profiles, with a strong linear Pearson correlation between control WT/HD gene ratios and N-PPG treated/control HD gene ratios.
Upregulated average tyrosine hydroxylase (Th) mRNA levels to 40% of control WT levels, dopamine receptor-1 (Drd1) to 44%, and adenosine A2A receptor (Adora2a) to 32% of control WT levels.
Increased kidney proline levels 1.4-fold, hydroxyproline 2.8-fold, and sarcosine 1.9-fold compared to vehicle control.
Animal Model: C57BL/6J (4-month-old, male and female; Grhpr knockout, fed 1% hydroxyproline diet)
Dosage: 200 mg/kg
Administration: p.o.; daily; 21 days
Result: Reduced urinary oxalate excretion by 31% after 9 days and 32% after 22 days compared to vehicle controls.
Reversed weight loss and induced weight gain, while vehicle controls continued to lose weight.
Increased hepatic hydroxyproline levels ~20-fold and proline levels ~10-fold compared to vehicle controls.
Significantly reduced liver glyoxylate levels compared to vehicle controls.
Reduced renal tubule calcium oxalate crystals by nearly 100-fold (fewer and smaller) compared to vehicle controls.
Drastically reduced urine kidney injury molecule-1 (KIM-1) levels and significantly lowered plasma Cystatin C levels compared to vehicle controls.
Showed minimal KIM-1 staining in kidney tissue, indistinguishable from wild-type mice.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 113.11
分子式 C5H7NO2
CAS No. 58160-95-5

储存&溶解度

储存方式

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 100 mg/mL (884.10 mM)

DMSO 中的溶解度 : 8.33 mg/mL (73.65 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM8.8410 mL44.2048 mL88.4095 mL221.0238 mL
5 mM1.7682 mL8.8410 mL17.6819 mL44.2048 mL
10 mM0.8841 mL4.4205 mL8.8410 mL22.1024 mL
15 mM0.5894 mL2.9470 mL5.8940 mL14.7349 mL
20 mM0.4420 mL2.2102 mL4.4205 mL11.0512 mL
25 mM0.3536 mL1.7682 mL3.5364 mL8.8410 mL
30 mM0.2947 mL1.4735 mL2.9470 mL7.3675 mL
40 mM0.2210 mL1.1051 mL2.2102 mL5.5256 mL
50 mM0.1768 mL0.8841 mL1.7682 mL4.4205 mL
60 mM0.1473 mL0.7367 mL1.4735 mL3.6837 mL
H2O80 mM0.1105 mL0.5526 mL1.1051 mL2.7628 mL
100 mM0.0884 mL0.4420 mL0.8841 mL2.2102 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础